

Company Profile

Industry Sector: Medical Devices

Company Overview: Pathfinder Therapeutics, Inc. (PTI) is an image-guided surgery company that has developed the first navigated abdominal surgery™ (NAS) system for soft-tissue applications. NAS involves the interactive use of images during a medical procedure, and is often referred to as "global positioning" (GPS) for surgery. In an automobile GPS, the current position of a vehicle is accurately localized or "registered" onto an electronic roadmap. As the automobile moves, its position is updated on this roadmap. The driver can use the GPS as a guide to see where their vehicle is, where it has been, and where it is headed, and follow a planned route to a selected destination. NAS allows the surgeon to accomplish the same thing with their surgical instruments, on the 3D "roadmap" of detailed medical images that are routinely acquired before the surgery. The SurgiSight Linasys™ (Liver NAVigation SYstem) is FDA cleared for image-guided open liver surgery. In addition, PTI has acquired FDA clearance for preoperative image surgical planning software for liver applications (PlaniSight Linasys™).

Target Market(s): Hospitals with general surgery & abdominal radiology depts.

Management

Leadership:

Skip Goode (President & CEO) – formerly VP of Sales for Medtronic SNT from 1999-2003 and VP of Accuray, Inc. from 2004-2008, both leaders in the field of image-guided surgery / therapy.

Jim Stefansic, PhD (COO) – co-founder of PTI, expert in NAS with over 15 years of experience.

Scientific Affiliates:

Washington Univ. in St. Louis (William Chapman, MD)

Memorial Sloan Kettering (William Jarnagin, MD)

Univ. of Florida Gainesville – Shands (Alan Hemming, MD)

Univ. of Pittsburgh Medical Center (David Geller, MD)

Key Value Drivers

Technology*: The SurgiSight Linasys™ software developed determines the current surgical position using a 3-D tracking system. Once the liver surface is localized in physical space using the tracking system and a laser range scanner, it is "registered" onto the medical images using complex algorithms. If this mapping is accurate, images that contain patient-specific information about the location of tumors or other critical structures such as blood vessels can be used as a guide by surgeons and provide more effective ablative or resection treatment for liver cancer. The PlaniSight Linasys™ preoperative planning device provides software that allows radiologists and surgeons to create and manipulate 3-D images of the liver for diagnosis and surgical planning.

Competitive Advantage: PTI has an exclusive license to intellectual property owned by Vanderbilt University for NAS and is the first company to acquire FDA clearance in the product code category OEW ("intraoperative software tissue tracking").

Plan & Strategy: Series B funding to commercialize new NAS technology and/or strategic partnering

*Technology funded by the NCI and being commercialized under the NIH-CAP

Product Pipeline



R&D Clinical Testing 510(k) Commercialization

Image-guided open liver surgery →

Image-guided kidney surgery →

Minimally invasive liver surgery →

Other abdominal organ applications